ABSTRACT
BACKGROUND: New skin and soft tissue infections (SSTI) guidelines were published in 2019 in France, changing the recommended duration for antibiotic treatment. The objective of the present study was to assess the impact of the publication of the 2019 French guidelines on SSTIs on the duration of antibiotic prescription for erysipelas. METHODS: In a before-after study (a year before and a year after April 1st, 2019), we included all adult patients diagnosed with erysipelas in Reims University Hospital medical wards and the emergency department. We retrospectively retrieved antibiotic prescription duration in the patients' medical files. RESULTS: Among 50 patients in the "before" and 39 in the "after" group, the mean duration of antibiotic prescription was significantly shorter in the "after" group (9.4 ± 2.8 vs. 12.4 ± 3.8 days, p = 0.0001). CONCLUSIONS: A 25% decrease in the duration of antibiotic prescription for erysipelas was observed following the implementation of these guidelines, providing useful information for an antibiotic stewardship policy.
Subject(s)
Erysipelas , Soft Tissue Infections , Adult , Humans , Anti-Bacterial Agents/therapeutic use , Erysipelas/drug therapy , Soft Tissue Infections/drug therapy , Soft Tissue Infections/diagnosis , Retrospective Studies , Controlled Before-After Studies , Prescriptions , Hospitals, UniversityABSTRACT
BACKGROUND: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. OBJECTIVE: To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. METHODS: A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. RESULTS: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938-30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635-21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158-13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. LIMITATIONS: Our follow-up period was 16 weeks and some late-onset time effects may still occur. CONCLUSION: This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.
Subject(s)
Conjunctivitis , Dermatitis, Atopic , Adult , Humans , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/diagnosis , Prospective Studies , Antibodies, Monoclonal, Humanized/adverse effects , Conjunctivitis/chemically induced , Conjunctivitis/epidemiology , Severity of Illness Index , Treatment OutcomeSubject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Pemphigoid, Bullous , Humans , Mucous MembraneSubject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Arthritis, Psoriatic/drug therapy , Colitis/chemically induced , Ileitis/chemically induced , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , C-Reactive Protein/analysis , Colitis/diagnostic imaging , Diarrhea/chemically induced , Female , Humans , IgA Vasculitis/chemically induced , Ileitis/diagnostic imaging , Middle Aged , Necrosis , Skin/pathology , Tomography, X-Ray Computed , Vasculitis, Leukocytoclastic, Cutaneous/diagnosisSubject(s)
Arthritis/etiology , Breast Neoplasms/complications , Granuloma Annulare/etiology , Paraneoplastic Syndromes/etiology , Arthritis/diagnosis , Biopsy , Breast Neoplasms/diagnosis , Breast Neoplasms/therapy , Female , Granuloma Annulare/diagnosis , Humans , Middle Aged , Paraneoplastic Syndromes/diagnosis , Remission Induction , Treatment OutcomeSubject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Melanoma/drug therapy , Mouth Neoplasms/drug therapy , Nivolumab/therapeutic use , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Skin Neoplasms/drug therapy , Aged, 80 and over , Female , Humans , Male , Melanoma/immunology , Melanoma/pathology , Middle Aged , Mouth Neoplasms/immunology , Mouth Neoplasms/pathology , Programmed Cell Death 1 Receptor/immunology , Remission Induction , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Treatment OutcomeABSTRACT
PURPOSE: To identify predictors of treatment success in syphilitic uveitis (SU). DESIGN: Retrospective multicentric analysis of patients treated for SU. PARTICIPANTS: A total of 95 eyes (66 patients, mean [standard deviation] aged 49 [12.5] years, 31 [47%] of whom were human immunodeficiency virus [HIV]+) were analyzed. METHODS: Activity of SU was assessed at 1 week and 1 month after treatment onset, and at last follow-up. Improvement was defined by a ≥2-step decrease of both anterior chamber and vitreous haze inflammation levels, and by the size reduction in chorioretinal lesions. MAIN OUTCOME MEASURES: Recovery was defined as the resolution of inflammation in all anatomic structures at 1 month. RESULTS: Panuveitis and posterior uveitis were the most frequent findings. Inflammatory parameters were higher in HIV+ patients. Recovery was reported in 65% and 85% of eyes at 1 month and at last follow-up, respectively. In multivariate analysis, after adjusting for initial best-corrected visual acuity and the antimicrobial treatment regimen, clinical improvement at 1 week (corrected risk ratios [cRR], 3.5 [2.3-3.8]; P = 0.001) was predictive of recovery at 1 month, whereas the use of periocular dexamethasone injections (cRR, 0.05 [0.02-0.6]; P = 0.01) and methylprednisolone pulses negatively affected the outcomes of eyes. CONCLUSIONS: Early improvement is the strongest predictor of ophthalmological recovery in SU.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Eye Infections, Bacterial/drug therapy , Syphilis/drug therapy , Uveitis/drug therapy , Adult , Azithromycin/therapeutic use , Doxycycline/therapeutic use , Eye Infections, Bacterial/diagnosis , Eye Infections, Bacterial/microbiology , Female , Fluorescent Treponemal Antibody-Absorption Test , Follow-Up Studies , HIV Seropositivity , Humans , Male , Middle Aged , Penicillin G Benzathine/therapeutic use , Polymerase Chain Reaction , Prognosis , Retrospective Studies , Sulfadiazine/therapeutic use , Syphilis/diagnosis , Syphilis/microbiology , Syphilis Serodiagnosis , Uveitis/diagnosis , Uveitis/microbiology , Visual Acuity/physiologyABSTRACT
BACKGROUND: Syphilis remains a significant public health problem. We conducted a prospective study to define more precisely the clinical and biological characteristics of patients with neurosyphilis (NS), and we assessed the diagnostic value of nested polymerase chain reaction (PCR) testing for Treponema pallidum in cerebrospinal fluid (CSF) samples. METHODS: From 2001 to 2013, we included 40 patients (90% men; 45% infected with human immunodeficiency virus) with NS, defined as syphilis with neurological and/or ophthalmological symptoms and CSF abnormalities. RESULTS: Thirty patients (75%) had early, 5 (12.5%) had late, and 5 had meningovascular NS. Twenty-four patients (80%) with early NS had ophthalmological symptoms, 14 (47%) had neurological symptoms, and 8 (26%) had both. All patients with meningovascular NS had only neurological symptoms. All patients with late NS had neurological symptoms, and 2 (40%) also had ocular symptoms. Ophthalmological symptoms were present in 65% of all patients with NS, and neurological symptoms in 60%. Seventeen patients (42.5%) had CSF white blood cell counts >20/µL (mean, 57/µL), and 27 (67.5%) had high CSF protein levels (>0.5 g/L; mean value, 1 g/L). CSF PCR results were positive in 42%, and CSF VDRL results in 30%. The nested PCR assay had an overall sensitivity of 42.5%, a specificity of 97%, a positive predictive value of 77%, and a negative predictive value of 86%. CONCLUSIONS: Early NS is the most frequent presentation, with an overrepresentation of polymorphous ophthalmological symptoms. PCR is highly specific and of potential value when used with other biological parameters.